



September 1, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Vide our letter dated May 5, 2023 (copy enclosed), we had informed the Stock Exchanges as regards Lupin Atlantis Holdings SA ('LAHSA'), Switzerland, wholly owned subsidiary of the Company, having entered into a Definitive Agreement, to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French Ministry of Economy and Finance.

We are now pleased to inform you that upon receipt of necessary approval from the French Ministry for the acquisition of shares in Medisol, an upfront payment of Euro 14.5 million (excluding working capital) has been made by LAHSA and the transaction is closed.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS -11973)**

Encl.:- a/a

May 5, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.



Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Dear Sir/Madam,

In compliance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, we are pleased to inform that the Company has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French Ministry of Economy and Finance. Particulars are as under: -

Name of the Acquirer - Lupin Atlantis Holding SA, Switzerland (wholly owned subsidiary of Lupin Limited)

| | | |
|-----------|--|--|
| a) | name of the target entity, details in brief such as size, turnover etc.; | Medisol, which was founded in 2011, specializes in generics injectables and is engaged in developing and commercializing its products, in pharmacies and hospitals in France. Revenues in 2022 were EUR 7.3 million (estimated). |
| b) | whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at 'arms-length'; | No. |
| c) | industry to which the entity being acquired belongs; | Pharmaceuticals. |
| d) | objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | With this acquisition, the Company will gain access to Medisol's portfolio of seven injectable products across four therapeutic areas, including pain management, anti-inflammatory, cardiovascular diseases and obstetrics. This has synergy with Lupin's injectables portfolio and other products. |

...2.

